In-Vitro Diagnostics Market Set for Steady Growth to US$ 131.68 Billion by 2032, Led by North America's 42.45% Market Share

The Global In-Vitro Diagnostics market reached US$ 84.90 billion in 2024 and is expected to reach US$ 131.68 billion by 2032, growing at a CAGR of 5.0% during the forecast period 2025-2032.

The market is steadily expanding as healthcare systems worldwide adopt advanced molecular diagnostics and point-of-care testing, driven by rising chronic disease prevalence, aging populations, and post-pandemic demand for rapid infectious disease screening. This growth underscores a shift toward personalized medicine and decentralized testing, enabling earlier interventions and improved patient outcomes in oncology, cardiology, and diabetes management.

Request Executive Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/in-vitro-diagnostics-market?ram

Key Industry Developments

United States:
✅ February 2026: Roche Diagnostics launched the cobas® liat Real-time PCR System expansion for rapid on-demand infectious disease testing, enhancing point-of-care diagnostics with AI-driven result interpretation to improve turnaround times in US clinical settings.

✅ January 2026: Beckman Coulter Diagnostics introduced RUO blood-based biomarker immunoassays for p-Tau217, GFAP, NfL, and APOE ε4, accelerating neurodegenerative research for Alzheimer's and related disorders.

✅ November 2025: Abbott unveiled next-gen Alinity m molecular diagnostics platform upgrade with expanded SARS-CoV-2/flu multiplex assays, improving throughput to 1,080 tests/hour for US hospital networks.

Japan:
✅ February 2026: Fujirebio Inc. (H.U. Group Holdings) released the LUMIPULSE® G system update for plasma phosphorylated tau assays, advancing Alzheimer's biomarker R&D with PMDA-approved automation for Japanese research institutes.

✅ December 2025: Sysmex Corporation announced Innova QX8000 Dx NGS platform launch tailored for Japan's oncology market, enabling comprehensive genomic profiling from FFPE samples in under 24 hours.

✅ October 2025: Toshiba (Canon Medical) debuted the V8 molecular diagnostics workstation with fully automated TB/MDR-TB detection, reducing hands-on time by 70% for Japan's TB control programs.

Strategic Acquisitions and Partnerships
✅ Waters Corporation acquired BD's Life Sciences business for $17.5 billion, expanding its clinical diagnostics capabilities in flow cytometry, single-cell biology, and microbiology diagnostics.

✅ Thermo Fisher Scientific pursued active M&A strategy, including acquisitions of 3M's Solventum purification and filtration business and Olink Proteomics' next-gen proteomics solutions to bolster its IVD portfolio.

✅ Danaher Corporation acquired Abcam plc for $24 per share, accelerating its in-vitro molecular diagnostic offerings and driving sales growth in the sector (announced December 2023).

Key Players:
bioMerieux | Becton, Dickinson and Company | Beckman Coulter, Inc. | F. Hoffmann-La Roche Ltd. | Bio-Rad Laboratories, Inc. | Abbott Laboratories | Qiagen NV | FUJIFILM Holdings Corporation | Sysmex Corporation | Siemens Healthineers AG

Strategic Leadership Analysis: Top 5 Players in In-Vitro Diagnostics Market 2026
-Roche Diagnostics: Launched the cobas liat SARS-CoV-2 & Influenza A/B Real-Time PCR Test, expanding syndromic molecular diagnostics for rapid respiratory pathogen detection in point-of-care settings to enhance clinical decision-making.

-Abbott Laboratories: Introduced the Alinity i system upgrade with enhanced immunoassay throughput and expanded menu for infectious disease and cardiac biomarkers, improving lab efficiency and turnaround times for high-volume testing.

-Siemens Healthineers: Advanced the Atellica IM 1300 analyzer with new assays for thyroid and reproductive health, delivering consolidated workflow solutions for mid-sized labs to streamline in-vitro diagnostics operations.

-Beckman Coulter: Rolled out the DxH 900 hematology analyzer featuring AI-driven morphology analysis and extended calibration stability, optimizing blood cell enumeration accuracy and reducing manual reviews in routine diagnostics.

-Bio-Rad Laboratories: Released the Reliance SARS-CoV-2/Flu/RSV RT-PCR test kit with multiplex detection capabilities, supporting comprehensive respiratory panel testing to aid in outbreak management and syndromic diagnosis.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=in-vitro-diagnostics-market?ram

Main Drivers and Trends Shaping the Future of In-Vitro Diagnostics Market
-Chronic Disease Surge: Rising prevalence of diabetes, cancer, and cardiovascular conditions worldwide drives demand for accurate, early diagnostic testing to enable timely interventions.

-Aging Population Impact: Global increase in elderly demographics heightens need for frequent screenings in oncology, cardiology, and metabolic disorders.

-Molecular Diagnostics Boom: PCR, next-generation sequencing (NGS), and liquid biopsies advance infectious disease detection and personalized oncology treatments.

-Point-of-Care Expansion: Compact, rapid POC kits enable testing in clinics, pharmacies, and homes, reducing healthcare system burdens.

-AI and Automation Integration: Machine learning enhances diagnostic speed, accuracy, and digital pathology, alongside cloud-connected platforms for remote monitoring.

-Market Hurdles: Stringent regulatory approvals, high R&D costs, supply chain vulnerabilities, and sustainability concerns over reagents and waste limit scalability.

Regional Insights:
-North America: 42.45% (Largest share, supported by advanced diagnostic infrastructure).​

-Asia Pacific: 21.95% (Fastest growing, driven by rapid healthcare expansion and rising diagnostic awareness).​

-Europe: 21.89% (Strong position via structured public healthcare systems and preventive testing).​

-South America: 5.30% (Emerging growth from clinical diagnostics access and lab expansion).​

-Middle East & Africa: 4.41% (Developing through improved healthcare coverage).​

Market Opportunities & Challenges: In-Vitro Diagnostics Market 2026
-Opportunities: A "Molecular Diagnostics Surge" accelerates adoption through next-gen sequencing for oncology and infectious disease panels, fueled by AI-enhanced bioinformatics platforms from Roche Diagnostics. Point-of-care expansions in emerging Asia-Pacific labs, backed by Abbott's rapid test innovations, enable decentralized testing amid rising chronic disease burdens.

-Challenges: Stringent FDA and EU MDR regulations delay novel companion diagnostic approvals, while reagent supply chain disruptions from geopolitical tensions inflate costs for Siemens Healthineers' immunoassay lines. High instrument pricing limits penetration in resource-constrained settings despite BD's automation pushes.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/in-vitro-diagnostics-market?ram

Market Segmentation Analysis:
-By Product Type: Reagents Dominate with Highest Volume
Reagents lead at 52% market share in 2024, essential for consumable test kits in routine diagnostics due to high usage frequency and recurring demand. Instruments follow at 25%, providing core analyzers for labs despite high upfront costs. Software/services claim 15%, enabling data integration and AI-driven analysis. Others hold 8%, covering disposables and accessories.

-By Technique Type: Immunoassays Command Broad Utility
Immunoassays top at 35%, excelling in protein/antibody detection for infectious and chronic diseases with high sensitivity. Molecular diagnostics take 25%, surging via PCR for genetic/pathogen testing. POC diagnostics grab 15% for rapid bedside results; hematology 10% for blood counts; tissue diagnostics 5%; microbiology 5%; self-blood-glucose 4%; others 1%.

-By Application: Infectious Diseases Lead Amid Global Health Focus
Infectious diseases hold 30% share, propelled by pandemics and routine screening needs. Diabetes follows at 20% via glucose monitoring; oncology 15% for tumor markers; cardiology 10%; autoimmune 8%; nephrology 7%; drug testing 5%; others 5%.

-By End-User: Hospitals Drive Core Volume
Hospitals dominate at 45%, centralizing high-volume testing in clinical settings. Diagnostic labs take 30% for specialized outsourcing; academics/research institutes 15% for R&D; others 10% including POC clinics.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.